Streamlined mAb Subunit LC-MS Workflow for Multiple Attribute Monitoring of Biosimilar mAb Candidates During Bioprocessing and Development
ZÁZNAM | Proběhlo Čt, 12.10.2023
Přejít na webinář

Waters Corporation: "Hear a customer perspective on deploying Waters solutions to enhance biosimilar development: Streamlined mAb Subunit LC-MS Workflow for Multiple Attribute Monitoring of Biosimilar mAb Candidates During Bioprocessing and Development"
Demonstration of an automated Protein A purification and LC-MS mAb subunit analysis of bioreactor samples to screen biosimilar monoclonal antibody (mAb) candidates in comparison to the innovator to support process development.
The method was demonstrated to have sufficient sensitivity and precision to quantitively assess N-linked oligosaccharides at levels known to impact pharmacokinetics and effector function activity, in addition to other post-translational modifications (PTMs) such as C-terminal lysine variants and other subunit-specific (LC & Fd’) modifications
Presenter: Jared Young (Similis Bio)

Waters Corporation